Hearing loss is the most common sensory disorder in humans. One in 500 newborns has hearing loss and that number increases to 1 in 100 children by school age. Clinical diagnosis often does not distinguish among different types of hearing loss. This is why we believe SEQaBOO may benefit the child and their family. Through genomic screening, we aim to provide optimal management at the earliest possible time for treatment and eliminate unnecessary tests and costs for you and your baby.
Universal newborn screening tests assess for rare but serious conditions in babies just after birth. All states require certain screening tests to be offered for newborns, even if they appear healthy. These generally include a variety of blood tests and a hearing screen. The Commonwealth of Massachusetts requires that all newborns be offered hearing screening prior to hospital discharge. Both the automated auditory brainstem response (AABR) and otoacoustic emissions (OAE) techniques are permissible in Massachusetts. If a newborn does not pass the in-hospital hearing screen, they are referred for a follow-up diagnostic audiology appointment at one of the Massachusetts Department of Public Health approved diagnostic audiology centers.
As part of standard care at Brigham and Women’s Hospital, every newborn has an automated auditory brainstem response hearing screen. Newborns who do not pass this initial hearing screen are scheduled at approximately one month of age for a follow-up hearing test with an Otolaryngologist.